| Home | E-Submission | Sitemap | Contact Us |  

doi: https://doi.org/10.4132/jptm.2020.09.23    [Epub ahead of print]
DNA-protein biomarkers for immunotherapy in the era of precision oncology
Binnari Kim1,2 , So Young Kang1 , Kyoung-Mee Kim1,3
1Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Pathology, Ulsan University Hospital, Ulsan, Korea
3Center of Clinical Genomics, Samsung Medical Center, Seoul, Korea
Corresponding Author: Kyoung-Mee Kim ,Tel: +82-2-3410-2807, Fax: +82-2-3410-6396, Email: kkmkys@skku.edu
Received: June 12, 2020;  Revised: September 7, 2020  Accepted: September 23, 2020.  Published online: November 9, 2020.
ABSTRACT
The use of biomarkers to guide patient and therapy selection has gained much attention to increase the scope and complexity of targeted therapy options and immunotherapy. Clinical trials provide a basis for discovery of biomarkers, which can then aid in development of new drugs. To that end, samples from cancer patients, including DNA, RNA, protein, and the metabolome isolated from cancer tissues and blood or urine, are analyzed in various ways to identify relevant biomarkers. In conjunction with nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided biomarker assays relying on protein-based immunohistochemistry play a pivotal role in cancer care. In this review, we discuss the current knowledge regarding DNA and protein biomarkers for cancer immunotherapy
Key Words: Biomarker; Clinical trial; Next-generation sequencing; Immunohistochemistry
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
0
Crossref
0
Scopus
371
View
24
Download
Related article